Abstract
To study whether a combination of the carriage of genetic blood markers: haptoglobin phenotypes and red blood cell glucose-6-phosphate dehydrogenase, 60 patients with destructive tuberculosis were given a new drug treatment regimen by using regional lymphotropic therapy with 10% isoniazid. The efficiency of the treatment and residual changes were found to be directly related to what a patient has as genetic background. Defining the types of combinations of genetic markers may predict the course of disease, the efficiency of treatment, and outcomes.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adolescent
-
Adult
-
Antitubercular Agents / administration & dosage*
-
Erythrocytes / enzymology
-
Female
-
Genetic Markers
-
Glucosephosphate Dehydrogenase / blood
-
Glucosephosphate Dehydrogenase / genetics*
-
Haptoglobins / genetics*
-
Haptoglobins / metabolism
-
Humans
-
Injections, Intralymphatic
-
Male
-
Middle Aged
-
Phenotype
-
Treatment Outcome
-
Tuberculosis, Pulmonary / blood
-
Tuberculosis, Pulmonary / drug therapy*
-
Tuberculosis, Pulmonary / genetics
Substances
-
Antitubercular Agents
-
Genetic Markers
-
Haptoglobins
-
Glucosephosphate Dehydrogenase